Diagnosis is the gateway to treatment, viral suppression and prevention. In 2015 pooled survey analysis across 16 sub‑Saharan African countries estimated that about 46% of people living with HIV (PLHIV) were undiagnosed, implying roughly 11 million individuals outside the care cascade in the region. WHO recommended ART for all and issued HIV self‑testing (HIVST) guidance in 2016, but population‑scale deployment of HIVST did not follow.
Estimated need for HIVST in low‑ and middle‑income countries (LMICs) was 177 million kits in 2020 rising to 192 million in 2025; confirmed procurement for the same period totaled 21 million kits (an average of 5.3 million/year), only about 3% of estimated annual need. By 2025 the diagnostic gap narrowed largely through facility‑based testing rather than HIVST: an estimated 2.6 million PLHIV in sub‑Saharan Africa and 4.9 million globally still did not know their status. The decade of delay likely produced avoidable illness, deaths and onward transmissions, although those outcomes were not formally modelled in the source.
Four structural failures underlie the missed opportunity and four policy actions are proposed to accelerate access and close the remaining gap.
Antiretroviral therapy (ART) prevents AIDS, reduces transmission and restores near‑normal life expectancy when taken and virally suppressive concentrations are achieved. Foundational cohort and randomized evidence demonstrated reduced linked transmission with viral suppression, culminating in trials and observational studies supporting the Undetectable = Untransmittable (U = U) message.
Diagnosis is the entry point to treatment and prevention. UNAIDS’ 90‑90‑90 target linked diagnosis, treatment and suppression and made closing the diagnostic gap the rate‑limiting step in prevention. WHO consolidated testing guidance in 2015 and recommended HIVST in December 2016 as an additional approach to expand access.
However, despite clear need and a technology designed to remove clinic barriers, HIVST was scaled cautiously, constrained by demonstration projects, supervised delivery expectations and conservative procurement, creating a long delay between evidence/policy and population‑level implementation.
HIV self‑testing (HIVST) enables an individual to collect their own specimen (oral fluid or blood), perform a rapid diagnostic test and interpret the result privately without attending a clinic or interacting with a healthcare worker. Self‑testing reduces barriers associated with facility‑based services, including disclosure of risk, health system navigation and concerns about confidentiality or household disclosure.
Regulatory and policy milestones included the US Food and Drug Administration approval of the first over‑the‑counter self‑test in July 2012 and WHO endorsement of self‑testing as an additional approach in 2016. WHO highlighted HIVST’s potential to reach people reluctant to use facility testing and to enable distribution via community networks, pharmacies, workplaces and peers.
The authors identify four structural failures that delayed population‑scale HIVST deployment:
Research capture: Demonstration projects and research initiatives substituted for systematic, scaled implementation. Rather than transitioning rapidly from trials to routine distribution, the field remained anchored to project‑level activity.
The supervised self‑testing paradox: Early programmatic emphasis on provider‑assisted or supervised self‑testing reintroduced clinic‑based steps HIVST was designed to avoid, undermining the modality’s private and community‑based advantages.
Procurement conservatism: Buyers pursued cautious procurement strategies that suppressed market signals and inhibited market development, limiting production, price competition and wide distribution.
Accountability and surveillance failure: There was no publicly accessible Africa‑level time series of HIVST volumes, preventing transparent measurement of scale and of the missed opportunity.
These failures interacted to keep HIVST deployment at negligible scale during a period when millions remained undiagnosed and when rapid scale could have complemented facility testing.
Decision‑making around HIVST deployment reflected power dynamics among donors, implementers, national programmes and market actors. Implementation geography and modality were shaped by these actors, with funders and research partners often preferring controlled demonstration models. This constrained widespread community distribution and delayed the shift to models that could reach general populations outside facility settings.
Procurement choices at global and national levels—driven by risk aversion, budget cycles and conservative demand forecasts—reduced incentives for manufacturers and distributors to scale production and lower costs. Consequently, market development lagged behind the policy endorsements.
The absence of mandatory, publicly reported HIVST commodity volumes at regional or Africa‑level meant that neither the global health community nor country stakeholders could easily quantify deployment at scale. The lack of transparent volume series made it difficult to hold institutions accountable or to document the scale of the missed opportunity. Where data existed, it were often limited to program reports, demonstration projects or supplier records rather than consolidated public datasets.
The article documents a large discrepancy between estimated need and actual procurement: need of 177–192 million kits per year in LMICs versus confirmed procurement of 21 million kits across 2020–2025. The authors state that the decade of delayed scale likely resulted in millions of avoidable illnesses, deaths and onward transmissions, but note that such impacts were not formally modelled within the Policy Forum.
The timeline presented contrasts rapid accumulation of evidence and successive WHO recommendations with very limited population‑level deployment, illustrating how policy advances were not matched by procurement, distribution and accountability mechanisms.
The authors propose four policy actions to expand HIVST access:
Mandatory public reporting of HIVST commodity volumes to create transparency and enable accountability.
A dedicated Africa‑specific distribution target of at least 50 million kits per year within the UNAIDS 95‑95‑95 framework to provide a clear market signal and programme goal.
Community‑based distribution as the default delivery model for the general population to leverage the modality’s strengths in privacy and reach.
Explicit HIVST volume commitments in the Global Health Security and Diplomacy (GHSD) 2026–2030 memoranda of understanding and work plans to secure institutional commitments and align funding and procurement.
These actions aim to correct the structural failures identified: improve surveillance and accountability, signal demand to markets, and shift delivery away from supervised, facility‑centric models toward community access.
HIVST has strong evidence and policy support and is particularly well suited to overcome barriers to clinic‑based diagnosis. Despite WHO endorsement in 2016, a combination of research‑centric implementation, supervised delivery expectations, procurement conservatism and lack of public volume data limited population‑scale rollout for roughly a decade. Estimated procurement dramatically lagged estimated need, and while the diagnostic gap narrowed by 2025, much of that progress was achieved through conventional testing at considerable cost.
The authors recommend clear, measurable actions—mandatory reporting, an Africa distribution target, community‑based defaults and formal GHSD commitments—to accelerate HIVST scale‑up and close remaining diagnostic gaps. The source notes that the health and transmission consequences of the delay were likely substantial but were not quantified in a formal model within the article.